Eli Lilly Soars on Weight Loss and Diabetes Drugs

The pharmaceutical giant's shares have climbed over 36% as its key products drive strong growth.

Jan. 27, 2026 at 10:55am

Got story updates? Submit your updates here. ›

Eli Lilly's momentum in weight loss and diabetes drugs has propelled the company to impressive financial results, with revenue growth of 54% year-over-year in Q3 2025 and earnings per share surging 127% in the first three quarters of the year. The company's flagship drugs Mounjaro and Zepbound have been the main drivers of this success, with sales increasing 94% and 209% respectively. Eli Lilly has also raised its full-year 2025 revenue guidance to a range of $63 billion to $63.5 billion, indicating continued strong growth.

Why it matters

Eli Lilly's dominance in the weight loss and diabetes medication markets highlights the company's ability to capitalize on two of the fastest-growing areas in healthcare. The company's success with these transformative products has the potential to solidify its position as a leader in the pharmaceutical industry.

The details

Eli Lilly's weight loss drug Mounjaro saw sales increase by 94% through the first three quarters of 2025, reaching $15.55 billion. Meanwhile, Zepbound, the company's weight loss-focused sister medication to Mounjaro, has been ramping up even faster, with sales jumping from just over $3 billion in the first three quarters of 2024 to $9.28 billion in the first three quarters of 2025.

  • Eli Lilly is expected to report earnings in the next few weeks.
  • The company raised its full-year 2025 revenue guidance to a range of $63 billion to $63.5 billion.

The players

Eli Lilly

A pharmaceutical company that is at the forefront of both diabetes and obesity medications.

Mounjaro

One of Eli Lilly's flagship drugs, which saw sales increase by 94% through the first three quarters of 2025.

Zepbound

Eli Lilly's weight loss-focused sister medication to Mounjaro, which has been ramping up even faster than Mounjaro.

Got photos? Submit your photos here. ›

What they’re saying

“Eli Lilly's momentum in weight loss and diabetes drugs remains exceptionally strong, and the company's third-quarter results highlight just how powerful this trend has become.”

— David Butler, Author (yahoo.com)

The takeaway

Eli Lilly's dominance in the weight loss and diabetes medication markets has driven impressive financial results, and the company's strong guidance suggests this momentum is likely to continue. The success of Mounjaro and Zepbound highlights Eli Lilly's ability to capitalize on two of the fastest-growing areas in healthcare, solidifying its position as a leader in the pharmaceutical industry.